

**VIRAL PSEUDO-CAPSIDS INCLUDING
ASSEMBLY AGONISTS AND ANTAGONISTS**

TECHNICAL FIELD OF THE INVENTION

The invention relates to recombinant viral proteins,
and more particularly, to recombinant viral capsid proteins
and methods that may be used in the development of new
5 antiviral agents.

This application is a conversion from and claims priority of U.S. Provisional Application Number 60/166,556, filed November 19, 1999.

Work resulting in the present invention was supported in part by a United States government grant NIH Pilot Project Grant under DHHS V19 A10035. Accordingly, the government has certain rights in the present invention.

5

BACKGROUND OF THE INVENTION

Without limiting the scope of the invention, its background is described in connection with viral capsid proteins and assays for inhibitors of viral assembly, as an example.

10

Structurally, viruses typically comprise at least a viral genome encapsidated within a proteinaceous shell termed the capsid. During virus assembly, individual constituent capsid proteins of one or more kinds associate with the viral genome in a coordinate fashion and assemble into a three-dimensional nucleocapsid structure. The nucleocapsid may be naked as with the very simple polio viruses or may be enveloped by one or more membranes

15

derived from the host cell as with herpes viruses. Virtually all phases of viral replication are dependant on the biochemical machinery of the infected host cell. As such, few chemotherapeutic agents are available that
5 selectively affect viral replication without considerable host toxicity. What is needed is a system for the generation of new antiviral agents that target unique viral replication events. The need is particularly acute for those viruses that cannot be readily grown in cell culture
10 and thus are not easily amenable to the development of antiviral agents that are both effective and host sparing.

SUMMARY OF THE INVENTION

The present invention is directed in part to the development of antiviral agents that are able to target a step in viral replication that may be considered relatively unique to the infecting virus, the step of assembly of virus encoded proteins into the virus nucleocapsid. Assembly of components into a complete virus particle is a critical step in the generation of new virus particles. Although virus assembly is a theoretical target for antiviral chemotherapeutics, lack of a viable *in vitro* assay adaptable to high throughput screening has thwarted the development of antivirals directed to blockage of viral assembly. In one embodiment of the present invention, a system for *in vitro* modeling of eukaryotic virus assembly is provided. Such an *in vitro* system may be particularly useful in the development of antiviral agents effective against viruses that cannot be grown in cell culture.

An example of one such virus, hepatitis C Virus ("HCV"), has emerged as a major public health threat. The inability to culture the virus *in vitro* has seriously hampered investigations into structural characteristics of

the viral core proteins and the development of effective antivirals. In one aspect of the present invention, a screening method and tool for the development of agents able to inhibit HCV maturation is provided.

5 HCV is an enveloped, single stranded positive sense RNA virus that has been placed in the Hepacivirus genus of the Flaviviridae family. HCV is a single capsid protein virus in which the nucleocapsid is formed from the assembly of multiples of a single capsid protein that assembles
10 together with the viral genome into a symmetrical geometric three-dimensional array. The term "capsid protein" is not necessarily synonymous with "core protein" as some viruses have additional "core proteins" included within the capsid or nucleocapsid. In the case of HCV however, "core" or
15 "core protein" has been used interchangeably with "capsid" or "capsid protein."

Due in part to the inability to cultivate the virus *in vitro*, the virus was definitively identified by molecular cloning of the viral genome (Choo, et al., Science 244:
20 359-62, 1989) in 1979. The genome consists of a 5' noncoding region followed by a single open reading frame

encoding encoding three structural proteins: a 23 kD
nucleocapsid (p22, core) and two envelope glycoproteins
(E1, E2), and four nonstructural proteins (NS2, NS3, NS4,
NS5) extending to the 3' end. Although the core protein
5 region is well conserved and invariable, the envelope
glycoproteins are hyper-variable.

Although humans infected with HCV generate an antibody
response to the envelope glycoproteins, due to the
hypervariability of these proteins, new variants are
10 constantly generated that are not recognized by existing
antibodies. As a consequence, most persons infected with
HCV are not able to eliminate the virus and develop chronic
infection that may go unrecognized for decades.
Ultimately, the chronic infection of the liver leads to
15 liver cirrhosis and hepatocellular carcinoma. The
hypervariability of HCV surface glycoproteins and the high
mutation rate of HCV complicate the development of a broad-
based surface antigen vaccine. The present system for
screening and development of antiviral agents directed to
20 the invariate core protein, including those able to block
the assembly of HCV, may be particularly useful given the

high morbidity and ultimate mortality associated with HCV infection.

In the United States, an estimated 1.8 % of the population, or 3.9 million individuals are infected with HCV. Liver disease resulting from HCV infection is responsible for approximately eight- to ten-thousand deaths annually. Within twenty years the number of deaths attributed to HCV infection is projected to triple. In the long term, the development of antiviral agents targeting invariable aspects of the virus, such as the highly conserved core or capsid proteins and/or their assembly into mature nucleocapsids will be needed to stem the projected HCV infection rates.

The present invention is directed to the development of antiviral agents for the treatment of hepatitis C virus infections and their benign and malignant sequelae by providing recombinant HCV capsid proteins that assemble *in vitro* to form large spherical virus-like particle ("LSVL") structures. Such structures have also been termed pseudo-capsids or pseudo-nucleocapsids herein. Such LSVL are a model of virus assembly and may be used for high throughput

screening for agents able to affect virus assembly in vivo. In one embodiment, the invention provides genetic constructs that include a polynucleotide sequence encoding at least a portion of a eucaryotic virus capsid polypeptide wherein said polypeptide is able to participate in formation of a LSVL in vitro. As one example of such a construct, genetic constructs including polynucleotides encoding the human hepatitis C capsid polypeptide and truncated portions thereof are provided.

10 In one embodiment of the present invention, a eukaryotic virus pseudo-nucleocapsid is provided that includes at least a portion of a viral capsid polypeptide and a polynucleotide wherein the viral capsid polypeptide and a polynucleotide is formed in vitro. As one example of
15 a pseudo-nucleocapsid formed according to the present invention, there is provided a LSVL formed by admixture of tRNA_{phe} with a COOH terminal truncation variant of HCV having the amino acid sequence of SEQ ID NO.: 1. Those of skill in the art will be able to find not only the
20 published sequence for the hepatitis C virus capsid protein and its variants, be also be able to select the best choice

of coding preferences for each amino acid based on the preferred usage of organisms for amino acids.

The invention also provides a system for isolating antagonists or agonists of viral capsid assembly that
5 includes the steps of; expressing a polynucleotide sequence encoding a recombinant viral capsid assembly polypeptide sequence in a archeal, prokaryotic, or eukaryotic host, purifying the viral capsid assembly polypeptide sequence, determining conditions enabling viral capsid or pseudo-
10 nucleocapsid assembly in vitro, and admixing potential antagonists or agonists to the determined conditions and measuring enhancement or derogation of viral capsid or pseudo-nucleocapsid assembly. In one embodiment, the determining conditions enabling viral capsid or pseudo-
15 nucleocapsid capsid assembly *in vitro* include determining the composition and quantity of a polynucleotide able to promote pseudo-nucleocapsid capsid assembly.

Also provided in one embodiment of the present invention is a system for isolating aptamers that may
20 function to catalyze viral capsid assembly. The system includes the steps of: (a) synthesizing a random

phosphodiester oligonucleotide library, (b) mixing the oligonucleotide library with a solution comprising one or more types of purified recombinant viral capsomer polypeptides, (c) separating pseudo-nucleocapsids formed, 5 (d) amplifying oligonucleotides associated with the separated pseudo-nucleocapsids to create a selected oligonucleotide sub-library, and as necessary, (e) repeating steps (b) - (d) iteratively until an aptamer population of defined sequence is obtained.

10 The present invention provides a model for the isolation of aptamers able to catalyze the formation of LSVL. It is anticipated that the present system may be applied to the generation of aptamers able to catalyze the formation of LSVL of a large number of viruses. Such LSVL 15 may be particularly useful in vaccine development against viruses, which are difficult to grow in cell culture or whose pathogenicity makes vaccine development hazardous.

In one embodiment, the present invention also provides a system for isolating aptamers that can function to 20 agonize or antagonize viral capsid assembly, including the steps of: (a) synthesizing a random phosphodiester

oligonucleotide library, (b) admixing the oligonucleotide library with a solution of recombinant viral capsid polypeptides, (c) isolating oligonucleotides bound to the viral capsid polypeptides, (d) amplifying oligonucleotides
5 associated with the separated viral capsid polypeptides to create a selected oligonucleotide sub-library, (e) repeating steps (b) - (d) iteratively until an aptamer population of defined sequence is obtained; (f) admixing aptamers of defined sequence obtained a viral pseudo-capsid
10 or nucleocapsid or the constituents thereof; and (g) determining which aptamers are able to agonize or antagonize viral pseudo-capsid or nucleocapsid formation.

According to the invention there is also provided a genetic construct that includes a nucleotide sequence
15 encoding a hepatitis C virus capsid assembly amino acid sequence ("CAS"), which is inserted into a transfer vector and operatively expressed by a promoter of that vector. The construct may be adapted, using techniques known in the art, for expression of the HCV CAS in archeal, prokaryotic
20 or eukaryotic cells

In one embodiment, the HCV CAS is isolated from a wild type HCV capsid gene. In a particular embodiment, the HCV CAS includes a nucleic acid sequence that encodes the polypeptide sequence of SEQ ID NO.: 1. The genetic
5 construct may further include other portions of the HCV genome.

According to another aspect of the invention, the invention provides a non-mammalian eukaryotic host cell transformed by the genetic constructs of the invention
10 including HCV CAS according to SEQ. ID. NO.: 1, or truncations thereof. Yet another aspect of the invention is a method for producing a recombinant HCV capsid protein, assembled into a large spherical virus-like ("LSVL") particle structure or a portion thereof, including the
15 steps of: (1) cloning a HCV gene that codes for the capsid protein into a transfer vector wherein the open reading frame of said gene is under the control of the promoter of said vector; (2) transferring the recombinant vector into a host cell, wherein the cloned HCV gene expresses the HCV
20 capsid protein; and (3) isolating large spherical virus-

like particles structures, that include the HCV capsid protein, from the host cell.

In one embodiment, the cloned hepatitis C virus gene has the conformational characteristics of the hepatitis C virus capsid coding sequence, and the expressed protein assembles into large spherical virus-like particles structures that include the capsid protein. In another embodiment, the cloning step further cloning a HCV gene coding for a truncated capsid protein, whereby said protein is expressed in the host cell and wherein the isolated LSVL particle include truncated capsid proteins. In one embodiment the transfer vector is the vaccinia virus. When a host cell is a mammalian cell, polyadenylation signals may be provided.

In another embodiment, the HCV capsid protein SEQ ID NO. 1 coding sequence is included in a vector in a host cell. The host cell into which the genetic construct is transfected may be, e.g., a prokaryotic or a eukaryotic cell. The transfer vector for use with the invention may be, e.g., a bacterial or a baculovirus based transfer vector. The hepatitis C virus capsid gene is under the

control of a promoter that is selected based in its activity in the host cell.

In an alternative embodiment of the method of the invention, the transfer vector is a yeast transfer vector, and the recombinant vector is transfected into yeast cells. According to yet another aspect of the invention there is provided a virus large spherical virus-like particles structure, or a portion thereof, including hepatitis C virus capsid protein, produced by the method the invention.

Alternatively, the virus large spherical virus-like particles structure can consist essentially of hepatitis C virus capsid proteins, produced by the method of the invention. In one particular embodiment, the virus large spherical virus-like particles structure includes a hepatitis C virus capsid protein that is the expression product of a capsid protein DNA cloned from a wild type virus. The virus capsids or large spherical virus-like particles structures of the invention, or portions or fragments thereof, may include of hepatitis C virus capsid protein. Alternatively, these capsids or large spherical

virus-like particles structures or their fragments may include wild type hepatitis C virus capsid protein.

The virus capsid structures according to any of the methods of the invention include capsid proteins having
5 immunogenic conformational epitopes capable of inducing neutralizing antibodies against native hepatitis C virus. In a preferred embodiment, the hepatitis C virus capsid protein is the expression product of a wild type HCV capsid gene.

10 According to yet another aspect of the invention there is provided a unit dose of a vaccine, comprising a peptide having conformational epitopes of a hepatitis C virus capsid protein, in an effective immunogenic concentration sufficient to induce a hepatitis C virus neutralizing
15 antibody when administered according to an immunizing dosage schedule. In one embodiment, the vaccine comprises a portion of the capsid protein sufficient for a LSVL capsid particle to be formed. In one embodiment, the vaccine includes a portion of the HCV capsid protein that
20 is a wild type HCV protein. Use of the HCV capsid open reading frame (ORF) from a wild type hepatitis C virus

genome, according to the methods of the invention, particularly facilitates the production of preparative amounts of virus-like particles on a scale suitable for vaccine use.

5 According to yet another aspect of the invention is a method of preventing or treating hepatitis C virus infection in a vertebrate. The treatment regime includes administering hepatitis C virus large spherical virus-like particles structure or a fragment thereof to a vertebrate
10 in a form and at a location that will maximize the immunogenicity of the particle. The treatment regimen will be designed to maximize the production of a cellular immune response as may be directed by the form, site and adjuvant used for inoculation.

15 The invention further provides a method of preventing or treating hepatitis C virus infection in a vertebrate, that includes the steps of, administering a hepatitis C virus large spherical virus-like particles structure of the invention, or a vaccine product comprising the large
20 spherical virus-like particles structure to a vertebrate, according to an immunity-producing regimen.

Also within the scope of the invention is a method for immunizing a vertebrate against hepatitis C virus infection, that includes administering to the vertebrate a recombinant genetic construct of the invention including a conformational hepatitis C virus coding sequence, and allowing the coding sequence to be expressed in the cells or tissues of the vertebrate, whereby an effective, neutralizing, immune response to hepatitis C virus is induced.

According to yet another aspect of the invention, there is provided a method of detecting hepatitis C virus in a specimen from an animal suspected of being infected with the virus, including contacting the specimen with antibodies having a specificity to one or more conformational epitopes of the capsid of said hepatitis C virus. The antibodies have a detectable signal producing label or are attached to a detectably labeled reagent, allowing the antibodies to bind to the hepatitis C virus, and determining the presence of hepatitis C virus present in the specimen using a detectable label.

According to yet another aspect of the invention, there is provided a method of determining a cellular immune response to hepatitis C virus in an animal suspected of being infected with the virus, that includes contacting
5 immunocompetent cells of said animal with a recombinant wild type hepatitis C virus capsid protein, or combined recombinant portion of a capsid protein according to the invention and assessing cellular or humoral immunity to hepatitis C virus by means of the proliferative response of
10 said cells to the capsid protein. The recombinant hepatitis C virus protein may be introduced into the animal, e.g., subcutaneously. The terms "contacted" and "exposed", when applied to a cell, are used herein to describe the process by which a hepatitis C viral capsid
15 protein or large spherical virus-like particle is delivered to a target cell or is placed in direct juxtaposition with the target cell.

A hepatitis C virus infection diagnostic kit is also a part of the invention. The diagnostic kit may include
20 large spherical virus-like particles structures that include the hepatitis C virus capsid protein, large

spherical virus-like particles structures that include hepatitis C virus proteins and capsid proteins or antibodies to either of these large spherical virus-like particles structures, singly or in combination, together
5 with materials for carrying out an assay for humoral or cellular immunity against hepatitis C virus, in a unit package container.

DETAILED DESCRIPTION OF THE INVENTION

While the making and using of various embodiments of the present invention are discussed in detail below, it should be appreciated that the present invention provides
5 many applicable inventive concepts that may be embodied in a wide variety of specific contexts. The specific embodiments discussed herein are merely illustrative of specific ways to make and use the invention and do not delimit the scope of the invention.

10 The present invention stems from a program to determine the structure of hepatitis C virus (HCV) core protein or proteins that are bound to the viral RNA sequence essential for genome encapsidation. These structural results are pivotal for the rational design of
15 oligonucleotide mimetics that will interfere with HCV genome recognition and packaging. The HCV core protein (amino acids 1-191) and C-terminally truncated core proteins were expressed in bacterial cells.

In one example, a truncated core protein HCVC-124
20 (corresponding to amino acids 2-124) and HCVC-179 (corresponding to amino acids 2-179) has been purified in

milligram quantities. Spectroscopic (i.e., CD, fluorescence, NMR), and analytical ultracentrifugation and X-ray crystallographic studies were conducted to determine the structure and solution properties of HCVC-124.

5 Purified HCV core protein may be used, e.g., in a PCR-based *in vitro* selection assay to identify the viral RNA encapsidation sequence. Purified HCV core protein will be incubated with the viral-based RNA aptamers, and used in X-ray crystallographic studies to determine the structure of
10 HCV core bound to RNA. The following definitions are used to define terms that will be used throughout the specification.

To facilitate the understanding of this invention, a number of terms are defined below. Terms defined herein
15 have meanings as commonly understood by a person of ordinary skill in the areas relevant to the present invention. Terms such as "a", "an" and "the" are not intended to refer to only a singular entity, but include the general class of which a specific example may be used
20 for illustration. The terminology herein is used to describe specific embodiments of the invention, but their

usage does not limit the invention, except as outlined in the claims.

As used throughout the present specification the following abbreviations are used: TF, transcription factor; 5 ORF, open reading frame; kb, kilobase (pairs); UTR, untranslated region; kD, kilodalton; PCR, polymerase chain reaction; RT, reverse transcriptase; LVSL, large spherical virus-like particles.

10 The term "LVSL" is used interchangeably herein with pseudo-capsid or pseudo-nucleocapsid. The term "capsid" refers to the protein shell that encloses the viral nucleic acid. The capsid is built of polypeptide units that cluster to form the morphological units seen by electron microscopy on the surface of particles and termed 15 "capsomers." The capsid together with its enclosed nucleic acid is called the "nucleocapsid."

Proteins are most easily characterized by their amino acid sequence or primary structure. Proteins typically develop intra and intermolecular relationships to form 20 secondary, tertiary and quaternary structures. A protein's secondary structure is the three dimensional structure of

constituent segments the protein (for example, an alpha helix, or a beta-sheet, or a beta-turn). Tertiary structure may be formed by virtue of interactions between secondary structural elements as well as between amino acid
5 side chains between amide bonds, of the protein. Proteins may also self-assemble, or alternatively, assemble with heterologous proteins into a quaternary structure. The amino acid sequence of the HCV core protein is an example of primary structure. The three-dimensional spheroid
10 assembly of HCV capsid or core proteins together with polynucleotide sequences into a "pseudo-nucleocapsid" is an example of quaternary structure.

The term "hepatitis C capsid protein" refers to the polypeptide as set forth (SEQ ID NO.:1) or a nucleic acid
15 sequence that encodes the protein essentially as set forth (SEQ ID NO.:1).

MSTNPKPQRL TCRNTNRRPQ DVKFPGGGQI VGGVYLLPRR GPRLGVRATR KTSERSNPRG
RRNPIPKARR PDGRTWANPG YPWPLYGNEG CGWAGWLLSP RGSRPSWGPT DPWRRSRNLG
KVIDTLTCGF ADLMGYIPLV GAPLGGAARA LAHGVRVLED GVNYATGNLP GCSFSIFLLA
LLSCLTVPAS A

The terms "a sequence essentially as set forth in SEQ ID NO. (#)", "a sequence similar to", "nucleotide sequence" and similar terms, with respect to nucleotides, refers to sequences that substantially correspond to any portion of the polypeptide sequence identified herein as SEQ ID NO.:1. These terms refer to synthetic as well as naturally-derived molecules and includes sequences that possess biologically, immunologically, experimentally, or otherwise functionally equivalent activity, for instance with respect to hybridization by nucleic acid segments, or the ability to encode all or portions of a hepatitis C capsid protein. Naturally, these terms are meant to include information in such a sequence as specified by its linear order.

The term "sequence similarity" refers to the extent to which two nucleic acids are complementary. There may be partial or complete sequence similarity. A partially complementary sequence is one that at least partially inhibits a completely complementary sequence from hybridizing to a target nucleic acid and is referred to using the functional term "substantially similar." The degree or extent of hybridization may be examined using a

hybridization or other assay (such as a competitive PCR assay) and is meant, as will be known to those of skill in the art, to include specific interaction even at low stringency. In the context of the present invention, a
5 functional similarity is found when the construct is capable of participating in formation of a LSVL in vitro.

The inhibition of hybridization of the completely complementary sequence to the target sequence may also be examined using a hybridization assay involving a solid
10 support (e.g., Southern or Northern blot, solution hybridization and the like) under conditions of low stringency. Low stringency conditions may be used to identify the binding of two sequences to one another while still being specific (i.e., selective). The absence of
15 non-specific binding may be tested by the use of a second target that lacks even a partial degree of complementarity (e.g., less than about 30% identity). In the absence of non-specific binding, the probe will not hybridize to the second non-complementary target and the original
20 interaction will be found to be selective.

Low stringency conditions are generally conditions equivalent to binding or hybridization at 42 degrees Centigrade in a solution consisting of 5XSSPE (43.8 g/l NaCl, 6.9 g/l $\text{NaH}_2\text{PO}_4\text{-H}_2\text{O}$ and 1.85 g/l EDTA, pH 7.4), 0.1% SDS, 5X Denhardt's reagent (50X Denhardt's contains per 500 ml: 5 g Ficoll (Type 400, Pharmacia), 5 g BSA (Fraction V; Sigma) and 100 micrograms/ml denatured salmon sperm DNA); followed by washing in a solution comprising 5X SSPE, 0.1% SDS at 42 degrees Centigrade when a probe of about 500 nucleotides in length is employed.

The art knows that numerous equivalent conditions may be employed to achieve low stringency conditions. Factors that affect the level of stringency include: the length and nature (DNA, RNA, base composition) of the probe and nature of the target (DNA, RNA, base composition, present in solution or immobilized, etc.) and the concentration of the salts and other components (e.g., formamide, dextran sulfate, polyethylene glycol). Likewise, the hybridization solution may be varied to generate conditions of low stringency hybridization different from, but equivalent to, the above listed conditions. In addition, the art knows

conditions that promote hybridization under conditions of high stringency (e.g., increasing the temperature of the hybridization and/or wash steps, inclusion of formamide, etc.).

5 An oligonucleotide sequence that is "substantially similar" to the hepatitis C capsid protein gene is defined herein as an oligonucleotide sequence that exhibits greater than or equal to 60% identity to the sequence of the hepatitis C capsid protein gene, when sequences having a
10 length of 100 bp or larger are compared. Substantial similarity may also be observed for sequences that form a functional capsid protein that is able to participate in formation of a LSVL in vitro.

15 The term "gene" is used to refer to a functional protein, polypeptide or peptide-encoding unit. As will be understood by those in the art, this functional term includes genomic sequences, fragments or combinations thereof, as well as gene products, including those that may have been altered by the hand of man. Purified genes,
20 nucleic acids, protein and the like are used to refer to these entities when identified and separated from at least

one contaminating nucleic acid or protein with which it is ordinarily associated.

As used herein, the term "vector" is used in reference to nucleic acid molecules that transfer DNA segment(s) from one cell to another. The vector may be further defined as one designed to propagate hepatitis C capsid protein sequences, or as an expression vector that includes a promoter operatively linked to the hepatitis C capsid protein sequence, or one designed to cause such a promoter to be introduced. The vector may exist in a state independent of the host cell chromosome, or may be integrated into the host cell chromosome

The term "recombinant" in the context of polypeptide coding regions and the polypeptides encoded by such coding regions refers to non-native products wherein the coding regions, and typically the expression thereof, have been manipulated *in vitro* by man to differ from their occurrence in nature. The viral capsid polypeptides of the present invention may be produced in a number of different recombinant systems as known in the art including archeal, prokaryotic, or eukaryotic. For examples not limiting on

the intended expression systems that may be utilized, bacterial, yeast, baculovirus, and mammalian vectors and corresponding host organisms may be utilized according to methods known in the art. For expression in an appropriate expression system, the desired viral capsid polypeptide coding regions are operably linked into an expression vector and introduced into a host cell to enable expression. The coding region with the appropriate regulatory regions will be provided in proper orientation and reading frame to allow for expression. Methods for gene construction are known in the art. See, in particular, Molecular Cloning, A Laboratory Manual, Sambrook et al, eds., Cold Spring Harbor Laboratory, Second Edition, Cold Spring Harbor, N.Y. (1989) and the references cited therein.

Where post-translational modification may be required for generating proteins of appropriate conformation, eucaryotic systems may be employed. Where desired, a baculovirus system known in the art may offer rapid cloning and high levels of expression including eucaryotic mechanisms for processing of proteins such as glycosylation

and phosphorylation. See, for example, Smith, et al., Mol. Cell Biol. (1985) 3:2156-2165.

5 The term "host cell" refers to cells that have been engineered to contain nucleic acid segments of the hepatitis C capsid protein, or altered segments, whether archeal, prokaryotic, or eukaryotic. Thus, engineered, or recombinant cells, are distinguishable from naturally occurring cells that do not contain recombinantly introduced genes through the hand of man.

10 The term "agonist" refers to a molecule that enhances either the strength or the time of an effect of hepatitis C capsid protein and encompasses small molecules, proteins, nucleic acids, carbohydrates, lipids, or other compounds. The term "antagonist" refers to a molecule that decreases
15 either the strength or the time of an effect of hepatitis C capsid protein and encompasses small molecules, proteins, nucleic, acids, carbohydrates, lipids, or other compounds.

The term "altered", or "alterations" or "modified" with reference to nucleic acid or polypeptide sequences is
20 meant to include changes such as insertions, deletions, substitutions, fusions with related or unrelated sequences,

such as might occur by the hand of man, or those that may occur naturally such as polymorphisms, alleles and other structural types. Alterations encompass genomic DNA and RNA sequences that may differ with respect to their
5 hybridization properties using a given hybridization probe. Alterations of polynucleotide sequences for hepatitis C capsid protein, or fragments thereof, include those that increase, decrease, or have no effect on functionality. Alterations of polypeptides refer to those that have been
10 changed by recombinant DNA engineering, chemical, or biochemical modifications, such as amino acid derivatives or conjugates, or post-translational modifications.

The present invention is a process for generating large spherical virus-like (LSVL) particles from purified
15 recombinant viral capsid proteins. In one embodiment of the present invention, LSVL particles are generated from purified recombinant hepatitis C virus (HCV) capsid proteins. The LSVL may be used as immunogens presenting capsid protein epitopes including epitopes existing as a
20 consequence of the assembly of individual capsid polypeptides into a quaternary structure. The LSVL

particles generated may be used in assays to identify inhibitors of viral assembly or disassembly, including in one embodiment, HCV assembly or disassembly. These assays are readily adapted to the high-throughput library-screening format favored by many pharmaceutical companies. Inhibitors of viral assembly or disassembly are potential antiviral agents. Inhibitors of viral assembly, "antagonists", may be expected to interfere with the formation of new virus particles or the completion of the viral replication cycle. Inhibitors, of viral disassembly, "agonists", may be expected to interfere with the uncoating of virus particles as they infect the cell thus preventing the encapsidated viral genome from initiating viral replication. Furthermore, inhibitors of viral disassembly, "agonists", may be expected to be useful in stabilizing the quaternary structure of viral pseudo-capsids such that when used in assays or as vaccines, they have prolonged self-life *in vitro* and have a prolonged biological half-life *in vivo* after administration. Where pseudo-capsids are used as gene delivery agents for *in vivo* gene transfer, the present system for the selection and isolation of

inhibitors of viral disassembly may be of particular utility.

The process of the present invention is used to generate LSVL particles, which may be incorporated into
5 assays used to identify inhibitors of viral assembly and disassembly. Furthermore, it is intended that the system of the present invention may be adapted for use with other viruses.

10 **Expression and Purification of Capsid Protein Variants**

The system disclosed herein begins with the expression and purification of recombinant variants of the HCV capsid protein. The expressed protein variants are HCV capsid proteins that are assembled into large spherical virus-like
15 (LSVL) particles. Intermolecular contacts within the LSVL particles may be similar to those that exist in the intact native virion. Assembly of LSVL particles is achieved by incubating recombinant HCV capsid protein with nucleic acids, e.g., oligonucleotides such as transfer RNA (tRNA).

20 The formation of LSVL particles in vitro is useful for the development of high throughput assays to identify

inhibitors of HCV assembly and disassembly. Compounds that suppress the formation of LSVL particles are potential inhibitors of HCV assembly ("antagonists"). Compounds that increase the formation of LSVL particles are potential inhibitors of HCV disassembly ("agonists"). The assembly of LSVL particles may be quantitated for example by a number of biochemical and biophysical methods, among them electron microscopy, velocity sedimentation, fluorescence emission, fluorescence polarization, and solution scattering. Since LSVL assembly may be monitored spectroscopically, the assembly of LSVL particles in high-throughput library screens may be monitored using available instrumentation (e.g., 96-well plate spectrofluorometers).

In operation, compounds from a chemical library are added to each well of a 96-well plate and the fluorescence polarization (excitation wavelength 290 nm, emission wavelength 335 nm) in each well is recorded. Recombinant HCV capsid proteins are added to each well and the fluorescence polarization measurement repeated. Increased polarization (relative to a control well) would highlight compounds that promote HCV capsid assembly, and hence are

potential inhibitors of HCV disassembly. Finally, tRNA is added to each well and the fluorescence polarization measurement repeated. Decreased polarization (relative to a control well) would highlight compounds that interfere with capsid assembly, and hence are potential inhibitors of HCV assembly. Thus, screening for inhibitors of assembly and disassembly would occur concurrently. As will be apparent to those of skill in the art, the present invention includes changing the order of the above steps so long as they do not affect the measured outcome of the present invention in high or even low throughput assay systems.

The present invention includes the designed and developed protocols for the expression, purification and solubilization of at least one recombinant HCV capsid protein. The system that was designed and developed, includes protocols for the *in vitro* assembly of recombinant HCV capsid protein. The assembly system developed was adapted for use in high-throughput library screening for inhibitors of HCV assembly.

An important feature of the present invention is the use of truncated HCV capsid protein (for example, the HCVC124 isolate includes only 65% of the native protein structure). Using the truncated capsid protein, large
5 spherical particles (50-200 nm in diameter) were generated that were amenable to characterization by light scattering and absorbance measurements. Furthermore, the LSVL particles form the basis of assays to identify inhibitors of HCV assembly and/or disassembly spontaneously formed in
10 vitro.

The expression, purification and solubilization of HCVC124 is described as follows. A recombinant protein was generated using standard molecular biologic techniques that includes residues 1 to 124 of the HCV capsid protein.
15 Coomassie blue-staining of an SDS-polyacrylamide gel showed that the purification of HCVC124 was successful (data not shown).

Cells from the glycerol stocks of the HCVC124 expressing isolate were grown overnight in 2xYT/Kan media
20 at 37°C, 300 rpm. The next morning the overnight culture was used to inoculate fresh 2xYT/Kan media. Typically, a

10 mL overnight culture was used to inoculate 500 mL uninduced culture. The inoculated culture was grown at 37°C, 300 rpm to an OD₆₀₀ of ~0.6 to ~0.8.

Next, protein expression was induced with 1 mM IPTG, followed by a three (3) hour incubation at 24°C (room temperature), 300 rpm. The cells were pelleted and frozen at -70°C. Next, the cell pellet was resuspended in 35 mL urea lysis buffer per 1L culture and sonicated. Urea lysis buffer is: 8M Urea (pretreated with Dowex MR-3 beads: 1 g beads per 100 mL solution), 25 mM Na phosphate pH 7.0, 250 mM NaCl, 2 mM EDTA, 2 mM DTT. The sonicated sample was centrifuged at 4°C for 20 minutes in the SS-34 rotor at 50,000 x g.

The supernatant was removed and saved at 4°C for cation exchange purification. The lysis pellet was resuspended again in urea lysis buffer and sonicated and centrifuged. The supernatant was saved for cation exchange. The supernatant was loaded on a cation exchange column (POROS 20 CM) equilibrated with 25 mM HEPES pH 7.0, 8 M urea. Protein was eluted with a linear gradient of NaCl (150 mM NaCl to 675 mM NaCl over 10 column volumes. Fractions

containing HCV capsid protein were pooled. Pooled sample was dialyzed overnight at 4°C against refolding buffer (20 mM Tris pH 7.0, 150 mM NaCl, 5 mM DTT) and then concentrated.

5 A concentrated sample was loaded on a C18 reverse-phase column (ODS-18) equilibrated with 20 mM NaPhos pH 3.0 and eluted with a linear gradient of methanol. Fractions containing HCV capsid protein were pooled, dialysed o/n, 4°C, against refolding buffer (20 mM Tris pH 7.0, 150 mM
10 NaCl, 5 mM DTT) and protease inhibitors were added to final concentrations 0.05mM Leupeptin (10 mM stock), 0.001 mM Pepstatin A (1 mM stock), 0.5 mM PMSF (100 mM stock) and then concentrated.

15 **Production of Full-Length and Core Protein Variants for Encapsidation Determinations**

The minimal viral RNA sequence necessary for the specific and high-affinity binding to HCV core protein may be determined using the assembly system. Analogous to
20 other enveloped RNA viruses, the packaging of HCV genome with core protein and the subsequent assembly of the

nucleoprotein capsid are believed to be initiated by specific and high-affinity binding of core protein to an RNA encapsidation sequence. Essential or preferential encapsidation sequences may be determined using PCR-based
5 *in vitro* selection against purified HCV core protein.

Using the truncated HCV protein variants, cocrystallization trials of the HCV core protein complexed with the RNA encapsidation sequence may be conducted. Purified HCV core protein is incubated with RNA
10 oligonucleotides containing the encapsidation sequence and used to generate protein crystals for x-ray crystallographic studies.

More specifically, an *E. coli* pET30 vector (Novagen) encoding the HCV core protein was constructed using the
15 polymerase chain reaction (PCR) methods from a template cDNA encoding capsid protein from HCV (strain AG94, genotype 1a). The cDNA was obtained from Dr. Stanley Lemon, UTMB Galveston. For one example of the optimization of protein expression and solubility, two HCV core protein
20 variants were created and analyzed. The predicated protein sequence of HCV core protein is shown in Figure 1a.

Underlined residues correspond to highly hydrophobic regions (calculated using Kyte-Doolittle parameters). Highlighted residues correspond to the carboxy terminus of the five proposed HCV core protein variants. Figure 1a-e shows the amino-acid sequences of these five variants: the full-length core protein (residues 1-191, 20.7 kD, SEG. ID. No.: 1), and carboxy terminus truncated variants $\Delta 12$ (residues 1-179, 19.6 kD, SEQ ID NO.: 1), and $\Delta 67$ (residues 1-124, 13.7 kD). Truncated core variants were chosen to either eliminate the long hydrophobic stretches of the protein (constructs $\Delta 67$) or to optimize protein expression (construct $\Delta 12$ and $\Delta 67$). DNA sequencing was conducted to confirm the authenticity of all constructs. These constructs were used to transform competent B21(DE3) cells for IPTG-induced expression of recombinant protein.

The recombinant core protein and the truncated variants have calculated isoelectric points of approximately 11.5. Given the high pI of the core protein relative to *E. coli* proteins, cation exchange chromatography may be used if desired to purify core protein from both the soluble and insoluble fractions of

the bacterial lysate resulting in substantial purification. Further purification may be performed using additional HPLC columns. Urea denatured core protein, purified from the insoluble fraction of the bacterial cell lysate, may be
5 refolded by dialysing against physiological buffers. The oligomeric and aggregation state of HCV core proteins may be determined using one or more analytical techniques including gel filtration chromatography, dynamic light scattering and analytical ultracentrifugation. The
10 existence of a folded domain may be assayed by tryptic digest. Circular dichroism (CD) spectroscopy may be used to quantitate the degree of secondary structure in these proteins.

Commercially available crystallization buffers
15 (Hampton Research) may be employed to examine a wide variety of solution conditions to generate crystals of purified HCV core protein constructs. X-ray diffraction data may be collected for example using MacScience DIP2030 type detectors or Bruker CCD-based type detectors.

20 A cDNA corresponding to the HCV genome may be used as a template for a modified "whole genome PCR" strategy to

generate a large number of cDNA fragments that completely span the viral genome. These cDNA fragments are transcribed into RNA and incubated with HCV core protein. Sequences that bind protein may be selected using a filter-
5 binding protocol. Since the filter selectively binds protein, RNA eluted from the filter will form an enriched sequence pool with affinity for core protein. The RNA is reverse transcribed, PCR amplified, transcribed and subjected to 2-10 cycles of increasingly stringent
10 selection (achieved through using limiting protein concentrations). In the final cycle, the amplified PCR products are cloned into *E. coli* and 10-20 colonies sequenced to identify a consensus binding site. Gel shift assays may be used to quantitate the binding affinity
15 between the corresponding RNA sequence and all soluble HCV core protein variants.

Generation of LSVL Particles from Purified Recombinant HCVC124

20 Nucleocapsid pseudo-particles are generated by mixing purified recombinant core protein or core protein

truncation variants with RNA under defined conditions. In one example, purified recombinant HCV capsid protein (HCVC124) was diluted in assembly buffer (100 mM KAcetate, 1.7 mM MgAcetate, 25 mM HEPES pH 7.4, 5 mM DTT) to a final concentration of approximately 1mg/ml Or 0.1mM. Oligonucleotides (e.g., tRNA_{Phe}, SIGMA) are resuspended in assembly buffer to a final relative ratio of 1/10 nucleotide to protein concentration. These amounts were found to be an example of an effective protein polynucleotide ratio. Equal volumes of the capsid protein and the RNA solutions were mixed together and incubated at 30°C for 10 minutes prior to transfer to 4°C for at least approximately 15 minutes before analysis. Electron microscopy of negative stained preparations comprising the mixture of HCVC124 capsid protein and tRNA showed the formation of spheroid LSVL particles (data not shown).

While this invention has been described in reference to illustrative embodiments, this description is not intended to be construed in a limiting sense. Various modifications and combinations of the illustrative embodiments, as well as other embodiments of the invention,

will be apparent to persons skilled in the art upon reference to the description. It is therefore intended that the appended claims encompass any such modifications or embodiments.

44

45

SEQUENCE LISTING

5 <110> Watowich, Stanley

Kunkel, Meghan

Lorinczi, Marta

10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
105
110
115
120
125
130
135
140
145
150
155
160
165
170
175
180
185
190
195
200
205
210
215
220
225
230
235
240
245
250
255
260
265
270
275
280
285
290
295
300
305
310
315
320
325
330
335
340
345
350
355
360
365
370
375
380
385
390
395
400
405
410
415
420
425
430
435
440
445
450
455
460
465
470
475
480
485
490
495
500
505
510
515
520
525
530
535
540
545
550
555
560
565
570
575
580
585
590
595
600
605
610
615
620
625
630
635
640
645
650
655
660
665
670
675
680
685
690
695
700
705
710
715
720
725
730
735
740
745
750
755
760
765
770
775
780
785
790
795
800
805
810
815
820
825
830
835
840
845
850
855
860
865
870
875
880
885
890
895
900
905
910
915
920
925
930
935
940
945
950
955
960
965
970
975
980
985
990
995
1000
1005
1010
1015
1020
1025
1030
1035
1040
1045
1050
1055
1060
1065
1070
1075
1080
1085
1090
1095
1100
1105
1110
1115
1120
1125
1130
1135
1140
1145
1150
1155
1160
1165
1170
1175
1180
1185
1190
1195
1200
1205
1210
1215
1220
1225
1230
1235
1240
1245
1250
1255
1260
1265
1270
1275
1280
1285
1290
1295
1300
1305
1310
1315
1320
1325
1330
1335
1340
1345
1350
1355
1360
1365
1370
1375
1380
1385
1390
1395
1400
1405
1410
1415
1420
1425
1430
1435
1440
1445
1450
1455
1460
1465
1470
1475
1480
1485
1490
1495
1500
1505
1510
1515
1520
1525
1530
1535
1540
1545
1550
1555
1560
1565
1570
1575
1580
1585
1590
1595
1600
1605
1610
1615
1620
1625
1630
1635
1640
1645
1650
1655
1660
1665
1670
1675
1680
1685
1690
1695
1700
1705
1710
1715
1720
1725
1730
1735
1740
1745
1750
1755
1760
1765
1770
1775
1780
1785
1790
1795
1800
1805
1810
1815
1820
1825
1830
1835
1840
1845
1850
1855
1860
1865
1870
1875
1880
1885
1890
1895
1900
1905
1910
1915
1920
1925
1930
1935
1940
1945
1950
1955
1960
1965
1970
1975
1980
1985
1990
1995
2000
2005
2010
2015
2020
2025
2030
2035
2040
2045
2050
2055
2060
2065
2070
2075
2080
2085
2090
2095
2100
2105
2110
2115
2120
2125
2130
2135
2140
2145
2150
2155
2160
2165
2170
2175
2180
2185
2190
2195
2200
2205
2210
2215
2220
2225
2230
2235
2240
2245
2250
2255
2260
2265
2270
2275
2280
2285
2290
2295
2300
2305
2310
2315
2320
2325
2330
2335
2340
2345
2350
2355
2360
2365
2370
2375
2380
2385
2390
2395
2400
2405
2410
2415
2420
2425
2430
2435
2440
2445
2450
2455
2460
2465
2470
2475
2480
2485
2490
2495
2500
2505
2510
2515
2520
2525
2530
2535
2540
2545
2550
2555
2560
2565
2570
2575
2580
2585
2590
2595
2600
2605
2610
2615
2620
2625
2630
2635
2640
2645
2650
2655
2660
2665
2670
2675
2680
2685
2690
2695
2700
2705
2710
2715
2720
2725
2730
2735
2740
2745
2750
2755
2760
2765
2770
2775
2780
2785
2790
2795
2800
2805
2810
2815
2820
2825
2830
2835
2840
2845
2850
2855
2860
2865
2870
2875
2880
2885
2890
2895
2900
2905
2910
2915
2920
2925
2930
2935
2940
2945
2950
2955
2960
2965
2970
2975
2980
2985
2990
2995
3000
3005
3010
3015
3020
3025
3030
3035
3040
3045
3050
3055
3060
3065
3070
3075
3080
3085
3090
3095
3100
3105
3110
3115
3120
3125
3130
3135
3140
3145
3150
3155
3160
3165
3170
3175
3180
3185
3190
3195
3200
3205
3210
3215
3220
3225
3230
3235
3240
3245
3250
3255
3260
3265
3270
3275
3280
3285
3290
3295
3300
3305
3310
3315
3320
3325
3330
3335
3340
3345
3350
3355
3360
3365
3370
3375
3380
3385
3390
3395
3400
3405
3410
3415
3420
3425
3430
3435
3440
3445
3450
3455
3460
3465
3470
3475
3480
3485
3490
3495
3500
3505
3510
3515
3520
3525
3530
3535
3540
3545
3550
3555
3560
3565
3570
3575
3580
3585
3590
3595
3600
3605
3610
3615
3620
3625
3630
3635
3640
3645
3650
3655
3660
3665
3670
3675
3680
3685
3690
3695
3700
3705
3710
3715
3720
3725
3730
3735
3740
3745
3750
3755
3760
3765
3770
3775
3780
3785
3790
3795
3800
3805
3810
3815
3820
3825
3830
3835
3840
3845
3850
3855
3860
3865
3870
3875
3880
3885
3890
3895
3900
3905
3910
3915
3920
3925
3930
3935
3940
3945
3950
3955
3960
3965
3970
3975
3980
3985
3990
3995
4000
4005
4010
4015
4020
4025
4030
4035
4040
4045
4050
4055
4060
4065
4070
4075
4080
4085
4090
4095
4100
4105
4110
4115
4120
4125
4130
4135
4140
4145
4150
4155
4160
4165
4170
4175
4180
4185
4190
4195
4200
4205
4210
4215
4220
4225
4230
4235
4240
4245
4250
4255
4260
4265
4270
4275
4280
4285
4290
4295
4300
4305
4310
4315
4320
4325
4330
4335
4340
4345
4350
4355
4360
4365
4370
4375
4380
4385
4390
4395
4400
4405
4410
4415
4420
4425
4430
4435
4440
4445
4450
4455
4460
4465
4470
4475
4480
4485
4490
4495
4500
4505
4510
4515
4520
4525
4530
4535
4540
4545
4550
4555
4560
4565
4570
4575
4580
4585
4590
4595
4600
4605
4610
4615
4620
4625
4630
4635
4640
4645
4650
4655
4660
4665
4670
4675
4680
4685
4690
4695
4700
4705
4710
4715
4720
4725
4730
4735
4740
4745
4750
4755
4760
4765
4770
4775
4780
4785
4790
4795
4800
4805
4810
4815
4820
4825
4830
4835
4840
4845
4850
4855
4860
4865
4870
4875
4880
4885
4890
4895
4900
4905
4910
4915
4920
4925
4930
4935
4940
4945
4950
4955
4960
4965
4970
4975
4980
4985
4990
4995
5000
5005
5010
5015
5020
5025
5030
5035
5040
5045
5050
5055
5060
5065
5070
5075
5080
5085
5090
5095
5100
5105
5110
5115
5120
5125
5130
5135
5140
5145
5150
5155
5160
5165
5170
5175
5180
5185
5190
5195
5200
5205
5210
5215
5220
5225
5230
5235
5240
5245
5250
5255
5260
5265
5270
5275
5280
5285
5290
5295
5300
5305
5310
5315
5320
5325
5330
5335
5340
5345
5350
5355
5360
5365
5370
5375
5380
5385
5390
5395
5400
5405
5410
5415
5420
5425
5430
5435
5440
5445
5450
5455
5460
5465
5470
5475
5480
5485
5490
5495
5500
5505
5510
5515
5520
5525
5530
5535
5540
5545
5550
5555
5560
5565
5570
5575
5580
5585
5590
5595
5600
5605
5610
5615
5620
5625
5630
5635
5640
5645
5650
5655
5660
5665
5670
5675
5680
5685
5690
5695
5700
5705
5710
5715
5720
5725
5730
5735
5740
5745
5750
5755
5760
5765
5770
5775
5780
5785
5790
5795
5800
5805
5810
5815
5820
5825
5830
5835
5840
5845
5850
5855
5860
5865
5870
5875
5880
5885
5890
5895
5900
5905
5910
5915
5920
5925
5930
5935
5940
5945
5950
5955
5960
5965
5970
5975
5980
5985
5990
5995
6000
6005
6010
6015
6020
6025
6030
6035
6040
6045
6050
6055
6060
6065
6070
6075
6080
6085
6090
6095
6100
6105
6110
6115
6120
6125
6130
6135
6140
6145
6150
6155
6160
6165
6170
6175
6180
6185
6190
6195
6200
6205
6210
6215
6220
6225
6230
6235
6240
6245
6250
6255
6260
6265
6270
6275
6280
6285
6290
6295
6300
6305
6310
6315
6320
6325
6330
6335
6340
6345
6350
6355
6360
6365
6370
6375
6380
6385
6390
6395
6400
6405
6410
6415
6420
6425
6430
6435
6440
6445
6450
6455
6460
6465
6470
6475
6480
6485
6490
6495
6500
6505
6510
6515
6520
6525
6530
6535
6540
6545
6550
6555
6560
6565
6570
6575
6580
6585
6590
6595
6600
6605
6610
6615
6620
6625
6630
6635
6640
6645
6650
6655
6660
6665
6670
6675
6680
6685
6690
6695
6700
6705
6710
6715
6720
6725
6730
6735
6740
6745
6750
6755
6760
6765
6770
6775
6780
6785
6790
6795
6800
6805
6810
6815
6820
6825
6830
6835
6840
6845
6850
6855
6860
6865
6870
6875
6880
6885
6890
6895
6900
6905
6910
6915
6920
6925
6930
6935
6940
6945
6950
6955
6960
6965
6970
6975
6980
6985
6990
6995
7000
7005
7010
7015
7020
7025
7030
7035
7040
7045
7050
7055
7060
7065
7070
7075
7080
7085
7090
7095
7100
7105
7110
7115
7120
7125
7130
7135
7140
7145
7150
7155
7160
7165
7170
7175
7180
7185
7190
7195
7200
7205
7210
7215
7220
7225
7230
7235
7240
7245
7250
7255
7260
7265
7270
7275
7280
7285
7290
7295
7300
7305
7310
7315
7320
7325
7330
7335
7340
7345
7350
7355
7360
7365
7370
7375
7380
7385
7390
7395
7400
7405
7410
7415
7420
7425
7430
7435
7440
7445
7450
7455
7460
7465
7470
7475
7480
7485
7490
7495
7500
7505
7510
7515
7520
7525
7530
7535
7540
7545
7550
7555
7560
7565
7570
7575
7580
7585
7590
7595
7600
7605
7610
7615
7620
7625
7630
7635
7640
7645
7650
7655
7660
7665
7670
7675
7680
7685
7690
7695
7700
7705
7710
7715
7720
7725
7730
7735
7740
7745
7750
7755
7760
7765
7770
7775
7780
7785
7790
7795
7800
7805
7810
7815
7820
7825
7830
7835
7840
7845
7850
7855
7860
7865
7870
7875
7880
7885
7890
7895
7900
7905
7910
7915
7920
7925
7930
7935
7940
7945
7950
7955
7960
7965
7970
7975
7980
7985
7990
7995
8000
8005
8010
8015
8020
8025
8030
8035
8040
8045
8050
8055
8060
8065
8070
8075
8080
8085
8090
8095
8100
8105
8110
8115
8120
8125
8130
8135
8140
8145
8150
8155
8160
8165
8170
8175
8180
8185
8190
8195
8200
8205
8210
8215
8220
8225
8230
8235
8240
8245
8250
8255
8260
8265
8270
8275
8280
8285
8290
8295
8300
8305
8310
8315
8320
8325
8330
8335
8340
8345
8350
8355
8360
8365
8370
8375
8380
8385
8390
8395
8400
8405
8410
8415
8420
8425
8430
8435
8440
8445
8450
8455
8460
8465
8470
8475
8480
8485
8490
8495
8500
8505
8510
8515
8520
8525
8530
8535
8540
8545
8550
8555
8560
8565
8570
8575
8580
8585
8590
8595
8600
8605
8610
8615
8620
8625
8630
8635
8640
8645
8650
8655
8660
8665
8670
8675
8680
8685
8690
8695
8700
8705
8710
8715
8720
8725
8730
8735
8740
8745
8750
8755
8760
8765
8770
8775
8780
8785
8790
8795
8800
8805
8810
8815
8820
8825
8830
8835
8840
8845
8850
8855
8860
8865
8870
8875
8880
8885
8890
8895
8900
8905
8910
8915
8920
8925
8930
8935
8940
8945
8950
8955
8960
8965
8970
8975
8980
8985
8990
8995
9000
9005
9010
9015
9020
9025
9030
9035
9040
9045
9050
9055
9060
9065
9070
9075
9080
9085
9090
9095
9100
9105
9110
9115
9120
9125
9130
9135
9140
9145
9150
9155
9160
9165
9170
9175
9180
9185
9190
9195
9200
9205
9210
9215
9220
9225
9230
9235
9240
9245
9250
9255
9260
9265
9270
9275
9280
9285
9290
9295
9300
9305
9310
9315
9320
9325
9330
9335
9340
9345
9350
9355
9360
9365
9370
9375
9380
9385
9390
9395
9400
9405
9410
9415
9420
9425
9430
9435
9440
9445
9450
9455
9460
9465
9470
9475
9480
9485
9490
9495
9500
9505
9510
9515
9520
9525
9530
9535
9540
9545
9550
9555
9560
9565
9570
9575
9580
9585
9590
9595
9600
9605
9610
9615
9620
9625
9630
9635
9640
9645
9650
9655
9660
9665
9670
9675
9680
9685
9690
9695
9700
9705
9710
9715
9720
9725
9730
9735
9740
9745
9750
9755
9760
9765
9770
9775
9780
9785
9790
9795
9800
9805
9810
9815
9820
9825
9830
9835
9840
9845
9850
9855
9860
9865
9870
9875
9880
9885
9890
9895
9900
9905
9910
9915
9920
9925
9930
9935
9940
9945
9950
9955
9960
9965
9970
9975
9980
9985
9990
9995
10000
10005
10010
10015
10020
10025
10030
10035
10040
10045
10050
10055
10060
10065
10070
10075
10080
10085
10090
10095
10100
10105
10110
10115
10120
10125
10130
10135
10140
10145
10150
10155
10160
10165
10170
10175
10180
10185
10190
10195
10200
10205
10210
10215
10220
10225
10230
10235
10240
10245
10250
10255
10260
1

<150> US 60/166556

5 <151> 1999-11-19

<160> 1

10

<170> PatentIn version 3.0

15

<210> 1

<211> 191

20

<212> PRT

<213> Hepatitis C virus

<400> 1

5 Met Ser Thr Asn Pro Lys Pro Gln Arg Leu Thr Cys Arg Asn Thr Asn

1 5 10 15

Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly

20 25 30

10

Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala

35 40 45

Thr Arg Lys Thr Ser Glu Arg Ser Asn Pro Arg Gly Arg Arg Asn Pro

15

50 55 60

Ile Pro Lys Ala Arg Arg Pro Asp Gly Arg Thr Trp Ala Asn Pro Gly

65 70 75 80

20 Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Cys Gly Trp Ala Gly Trp

85 90 95

Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Thr Asp Pro

100 105 110

Trp Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys

115

120

125

5 Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu

130

135

140

Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp

145

150

155

160

10

Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile

165

170

175

Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser Ala

15

180

185

190